VX1:F:F-Vertex Pharmaceuticals Incorporated (EUR)

COMMON STOCK | Biotechnology |

Last Closing

USD 433.35

Change

0.00 (0.00)%

Market Cap

USD 114.63B

Volume

10.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-07 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NOV:F Novo Nordisk A/S

-0.20 (-0.19%)

USD 474.00B
NOVA:F Novo Nordisk A/S

+0.50 (+0.48%)

USD 471.87B
RGO:F Regeneron Pharmaceuticals Inc

-17.00 (-1.81%)

USD 104.28B
CSJA:F CSL LTD SPON.ADR 2

N/A

USD 85.13B
CSJ:F CSL Limited

N/A

USD 85.06B
DUL:F Alnylam Pharmaceuticals Inc

-1.30 (-0.53%)

USD 31.84B
UNC0:F UCB S.A. UNSP.ADR 1/2

+1.00 (+1.24%)

USD 30.73B
1AEA:F argenx SE

-6.00 (-1.22%)

USD 29.94B
1AE:F Argen-X

+2.60 (+0.53%)

USD 29.76B
22UA:F BioNTech SE

+0.40 (+0.36%)

USD 25.58B

ETFs Containing VX1:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 17.23% 75% C 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.23% 74% C 69% C-
Trailing 12 Months  
Capital Gain 39.79% 83% B 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.79% 83% B 77% C+
Trailing 5 Years  
Capital Gain 173.82% 82% B 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 173.82% 81% B- 82% B
Average Annual (5 Year Horizon)  
Capital Gain 20.96% 86% B+ 86% B+
Dividend Return 20.96% 86% B+ 80% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 32.16% 51% F 37% F
Risk Adjusted Return 65.17% 96% N/A 86% B+
Market Capitalization 114.63B 100% F 99% N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.